Letters

Ebola Diagnostics
It appears that there were omissions in your recent article on Ebola diagnostics ("Ebola Outbreak Spurred Sequencing and Diagnostic Efforts," June 2015, p. 226). In the article, the author did not discuss the simple, sample-to-answer Ebola Zaire virus nucleic acid amplifı-cation tests that have already been issued Emergency Use Authorization by the FDA: Xpert® Ebola (Cepheid, Sunnyvale, Calif.) and FilmArray Biothreat-E Test® (BioFire Defense LLC, Salt Lake City, Utah). Both of these moderate-complexity tests are capable of near-care or point-of-care testing on whole blood, with minimal hands on time and results in 1 to 2 hours. Xpert® Ebola was developed with grants provided by the Bill and Melinda Gates Foundation and Paul Allen Family Foundation, and is undergoing fıeld evaluation in Sierra Leone.
Benjamin Pinsky Stanford University School of Medicine
The Early Challenges of Antibiotic Discovery
Professor Kim Lewis' excellent review of the status of antibiotic research ("Challenges of Antibiotic Discovery," Microbe, September 2015, p. 363-369) unfortunately includes a common microbiological misconception that should be addressed. He comments that Selman Waksman "introduced a simple screen which essentially replicates the accidental discovery of Fleming-a Streptomyces spot-inoculated on a plate with a lawn of the test pathogen, and a zone of growth inhibition indicates the presence of an antibiotic." However, the variety of complex twists Brunswick, N.J., 1945) . In 1952 the Nobel Committee awarded the Nobel Prize in Physiology or Medicine to Selman Waksman for his "ingenious systematic and successful studies of soil microbes that led to the discovery of streptomycin." Likewise, this year the Nobel Prize in Physiology or Medicine was in part awarded to Satoshi mura for the discovery of Avermectin, and the Nobel Assembly cited Dr. mura's "extraordinary skills in developing unique methods" for the isolation of Streptomyces species. Screening methodology merits focus.
The variations in methodology of Waksman's "simple screen," which led to the discovery of many antibioticproducing actinomycetes and fungi, were complex and required the combined efforts of a remarkable team. Waksman's team at Rutgers used a variety of screening approaches, including: directly plating soil, using soils enriched with Escherichia coli to enhance antagonists active towards gram-negative pathogens, and recovery using selective media containing turbid suspensions of washed live target bacteria combined with phosphate and cleaned agar. In spite of the complex screening methods, it is ironic that one of the two original Rutgers streptomycin-producing Streptomyces griseus strains (D-1) was obtained from a chicken tracheal swab that was plated onto nutrient agar where it showed microbial antagonism (D. Jones, M.S. Thesis, Rutgers, the State University of New Jersey, New Brunswick, N.J., 1945 mycin that was active towards all three groups. Eureka! The discovery of the fırst broad-spectrum antibiotic and validation of the Waksman screening concept. Unfortunately, actinomycin was toxic in the subsequent animal trials. In continuing the development of screening methodology, Elizabeth Horning (E. S. Horning, Ph.D. Thesis, Rutgers, the State University of New Jersey, New Brunswick, N.J., 1942) addressed antagonistic fungi and bacteria. For fungi, she speeded up the procedure by sidestepping the severalweek soil enrichment step and plated soil directly onto bacteria seeded plates. Any fungal antagonists (clearing zones) were subcultured onto dextrose peptone agar in an attempt to enhance antibiotic production. After incubation, these fungal plates were streak inoculated with Bacillus subtilis or Staphylococcus aureus up to the edge of the fungus colony. The fungi producing clearing zones were transferred to dextrose-peptone or Czapek agar. Horning discovered the antibiotics clavacin (Penicillium notatum) and fumigacin (Aspergillus fumigatus). She also addressed antagonistic actinomycetes by plating soils, lake mud, composts, and one bacterially enriched soil onto albumin and Krainsky agars. She recovered over 100 inhibitory strains, coincidentally showing that roughly 30% of the soil actinomycetes had inhibitory activities. However, the singular experiment using potting soil enriched with mixtures of bacteria, revealed that 93% of the recovered actinomycetes showed antagonism.
At this stage Waksman fully directed his attention to his beloved actinomycetes (S. A.Waksman and A. T. Henrici, J. Bacteriol. 46:337-341, 1943). Albert Schatz continued the primary direct screening method onto E. coli or M. tuberculosis based media and then with subsequent analysis of isolates using the cross streak plate method and also testing in liquid media (A. Schatz, Ph.D. Thesis, Rutgers, the State University of New Jersey, New Brunswick, N.J., 1945). Interestingly, he did not recover any antagonistic isolates from the tubercule plates. He isolated the S. griseus strains 18 -16 and D-1, which displayed activities towards E. coli. S. griseus 18 -16 was discovered through plating on E. coli turbid medium, but grew sparsely and without a clearing zone, and therefore, this strain may not have been discovered by a modern high-throughput screen. It was selected simply based on its sparse growth with E.coli cells as a source of nutrient. S. griseus D-1 was initially observed through plating from a chicken throat swab directly onto nutrient agar where it was antagonistic to other throat organisms These two cultures produced the broad-spectrum antibiotic streptomycin, which was active towards both gram-positive and gramnegative bacteria, as well as tubercule bacteria. Eureka II! The discovery of streptomycin rocketed the screening for broad-spectrum antibiotics and revamped the pharmaceutical industry, which resulted in the discovery of diverse antibiotics resulting in a paradigm shift in medicine and society.
The dramatic rise of multiple antibiotic-resistant pathogens remains a driving force for the discovery of new antibiotics (reviewed in S. B. Levy, The antibiotic paradox: how miracle drugs are destroying the miracle. Plenum Press, New York, 1992 We also note that Selman Waksman's name and S. griseus were unfortunately misspelled in the article (Waxman and gryseus, respectively). Lewis' report excellently represents the status of today's antibiotic discovery and we applaud his group's efforts and successes in bringing forth new and novel drugs from dirt, and thereby, revitalizing the interest in this important fıeld of study. Sequence data of small subunit rRNA (16S rRNA for prokaryotes, 18S rRNA for eukaryotes) are an integral part of every paper describing new species of microorganisms. And because of the availability of extensive ribosomal RNA sequence databases, most "cultivationindependent" studies of microbial communities in natural environments target 16S or 18S rRNA genes. I estimate that 16S or 18S rRNA genes feature in at least 70 -80% of all papers in journals such as FEMS Microbiology Ecology, ISME Journal, and Microbial Ecology.
Douglas Eveleigh
Although the great majority of microbiologists use the terms 16S and 18S rRNA daily, hardly anybody appears to know what the "S" stands for. To prove this fact I devised a little quiz. The question asked was: "What is the dimension of the "S" unit (as used in 16S rRNA, 70S ribosomes, etc.) in SI Units (kg ϭ kilogram; m ϭ meter, s ϭ second)". I presented the following options: (1), Dimensionless; (2), kg; (3), m; (4), s; (5), kg/m; (6), kg/m 2 , (7)
